Ameliorates symptoms in EAE, an animal model of MS.
Pipeline
Down-regulates pro-inflammatory immunomodulators
Promotes neuron preservation and remyelination
Crosses the Blood Brain Barrier
Our pipeline
Relaxin is a first-in-class drug candidate with disease modifying potential for the treatment of relapsing remitting and progressive forms of multiple sclerosis, concussion and other neurodegenerative conditions of. Phase 2a studies in acute relapse in MS and concussion to be initiated in 2026.
Relaxin is a peptide hormone which is up- regulated in pregnancy – when MS symptoms improve.
Relaxin is pleiotropic in nature, acting as an agonist for the glucocorticoid receptor (GCR), the relaxin family peptide receptor 1 and the Peroxisome proliferator activated receptor gamma (PPARγ).
Strong Intellectual Property
MECHANISM OF ACTION
Through the glucocorticoid receptor, the relaxin family peptide receptor 1 and the peroxisome proliferator-activated receptor gamma, relaxin modulates the immune system, inhibits cell-mediated pro-inflammatory activity, is neuroprotective, promotes remyelination, controls microglial polarization and inhibits tau deposits.
BVBiomedical Ltd. is a research driven company developing novel therapeutic compounds for use in treating neuro-degenerative diseases.
Contacts
-
- Address
- Magdalen Centre, The Oxford Science Park, Robert Robinson Drive, Oxford, Oxfordshire OX4 4GA, U.K.
-
- Phone
-
- +44 751 879 5083
-
- info@bvbiomed.com